79 related articles for article (PubMed ID: 36483433)
1. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
3. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study.
Ghosh S; Antunes A; Rinta-Kokko H; Chaparova E; Lay-Flurrie S; Tricotel A; Andersson FL
Int J Infect Dis; 2024 May; 142():106967. PubMed ID: 38368927
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Patients With Initial
Guh AY; Li R; Korhonen L; Winston LG; Parker E; Czaja CA; Johnston H; Basiliere E; Meek J; Olson D; Fridkin SK; Wilson LE; Perlmutter R; Holzbauer SM; D'Heilly P; Phipps EC; Flores KG; Dumyati GK; Pierce R; Ocampo VLS; Wilson CD; Watkins JJ; Gerding DN; McDonald LC
Open Forum Infect Dis; 2024 Apr; 11(4):ofae127. PubMed ID: 38577028
[TBL] [Abstract][Full Text] [Related]
5. Case Series: Efficacy of Polyclonal Intravenous Immunoglobulin for Refractory
Ragan SA; Doyle C; Datta N; Abdic H; Wilcox MH; Montgomery R; Crusz SA; Mahida YR; Monaghan TM
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651406
[TBL] [Abstract][Full Text] [Related]
6. Microbiota-Based Live Biotherapeutic Products for
Monday L; Tillotson G; Chopra T
Infect Drug Resist; 2024; 17():623-639. PubMed ID: 38375101
[No Abstract] [Full Text] [Related]
7. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Feuerstadt P; Allegretti JR; Dubberke ER; Guo A; Harvey A; Yang M; Garcia-Horton V; Fillbrunn M; Tillotson G; Bancke LL; LaPlante K; Garey KW; Khanna S
Infect Dis Ther; 2024 Jan; 13(1):221-236. PubMed ID: 38236515
[TBL] [Abstract][Full Text] [Related]
8. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis.
Reveles KR; Yang M; Garcia-Horton V; Edwards ML; Guo A; Lodise T; Bochan M; Tillotson G; Dubberke ER
Adv Ther; 2023 Jul; 40(7):3104-3134. PubMed ID: 37210680
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and microbiota-based therapies for
Chopra T; Hecht G; Tillotson G
Front Med (Lausanne); 2022; 9():1093329. PubMed ID: 36698844
[No Abstract] [Full Text] [Related]
10. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
11. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
13. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
14. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
15. Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with
Amin A; Nelson WW; Dreyfus J; Wong AC; Mohammadi I; Teigland C; Dahdal DN; Feuerstadt P
Ther Adv Infect Dis; 2022; 9():20499361221095679. PubMed ID: 35510091
[TBL] [Abstract][Full Text] [Related]
16. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.
Feuerstadt P; Nelson WW; Drozd EM; Dreyfus J; Dahdal DN; Wong AC; Mohammadi I; Teigland C; Amin A
J Am Med Dir Assoc; 2022 Oct; 23(10):1721-1728.e19. PubMed ID: 35288083
[TBL] [Abstract][Full Text] [Related]
17. Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015-2020.
Okafor CM; Clogher P; Olson D; Niccolai L; Hadler J
Emerg Infect Dis; 2023 May; 29(5):877-87. PubMed ID: 37081745
[TBL] [Abstract][Full Text] [Related]
18. The burden of CDI in the United States: a multifactorial challenge.
Feuerstadt P; Theriault N; Tillotson G
BMC Infect Dis; 2023 Mar; 23(1):132. PubMed ID: 36882700
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
